Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

A new study in mice shows that tirzepatide—the active ingredient in the popular drugs Mounjaro and Zepbound—not only helps shed pounds but may also slow or reduce the growth of breast cancer tumors ...

DIY tirzepatide, internet detective work and insurance appeals: The lengths 3 people are going to for weight loss drugs "Not being on it is not an option." ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to access life-changing weight loss medications.

It's a trend ... or untested tirzepatide. The company said it is filing lawsuits, educating consumers and working with social media companies to identify and remove posts that promote unsafe products, ...

Beauty guru Avrey Ovard experiments with a DIY mullet and shares what it taught her.

Analyst Ratings Published06/12/2025, 11:24 AM Eli Lilly stock holds Buy rating at UBS amid tirzepatide vial-splitting trend View all comments (0)0 LLY 0.44% ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight loss in a real-world setting because patients discontinue treatment or ...